Therapie der juvenilen idiopathischen Arthritis (JIA)

ZUSAMMENFASSUNG

Die Behandlung der juvenilen idiopathischen Arthritis (JIA) hat sich in den vergangenen 2 Jahrzehnten u. a. durch die Verfügbarkeit neuer Substanzen entscheidend verändert. Trotz vorhandener Zulassungen, die sich teilweise aus der Behandlung der rheumatoiden Arthritis ableiten, sind zur Einordnung der vorhandenen Evidenz Leitlinien eine wichtige Entscheidungshilfe. Die 2012 publizierte AWMF-Leitlinie zur „Therapie der juvenilen idiopathischen Arthritis“ wurde zwischen 2018 und 2019 in einem mehrstufigen Prozess aktualisiert und als S2k-Leitlinie aktualisiert. Wichtige Prinzipien und Empfehlungen zur medikamentösen und nicht-medikamentösen Therapie der JIA wurden verabschiedet. Im Fokus all dieser Maßnahmen bleibt die rasche Entzündungskontrolle, der Remissionserhalt, die Vermeidung von krankheits- und therapiebedingten Folgeschäden sowie die Gewährleistung einer störungsfreien somatischen und psychosozialen Entwicklung, Lebensqualität und Teilhabe der betroffenen Kinder und Jugendlichen.

ABSTRACT

The therapy of juvenile idiopathic arthritis (JIA) has undergone significant changes during the past two decades also due to the availability of new biologic substances. Therapy guidelines gathering the available evidence are crucial for clinical decision-making. The current interdisciplinary therapy guideline was updated between 2018 and 2019 in different steps, leading to an updated adoption of recommendations and principles of medical and non-medical therapy of JIA. The main focus and goal of all therapeutical considerations remains a rapid control of inflammation leading to and maintaining remission while avoiding disease or therapy-associated damage. This shall furthermore allow an appropriate somatic and psycho-social development along with an adequate health-related quality of life and participation of children and adolescents with JIA.

Schlüsselwörter

Juvenile idiopathische Arthritis - Therapie - Leitlinien

Keywords

Juvenile idiopathic arthritis - therapy - therapy guidelines

• Literatur

• 1 Petty RE, Southwood TR, Manners P. et al International League of Associations for Rheumatology. J Rheumatol 2004; 31 (02) 390-392
• 2 Ravelli A, Consolaro A, Horneff G. et al Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis 2018; 77: 819-828
• 3 Hissink Muller P, Brinkman DMC, Schonenberg-Meinema D. et al Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. Ann Rheum Dis 2019; 78 (01) 51-59
• 4 Minden K, Horneff G, Niewerth M. et al Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young Adulthood. Arthritis Care Res (Hoboken) 2019; 71 (04) 471-481
• 5 Consolaro A, Ruperto N, Bazso A. et al Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 658-666
• 6 Dueckers G, Guellac N, Arbogast M. et al Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 2012; 142: 176-193
• 7 Guellac N, Niehues T. Interdisziplinäre S2-Therapieleitlinie der Juvenilen idiopathischen Arthritis. Klin Padiatr 2008; 220 (06) 392-402
• 8 Magnani A, Pistorio A, Magni-Manzoni S. et al Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. J Rheumatol 2009; 36: 628-634
• 9 Simard JF, Neovius M, Hagelberg S. et al Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 2010; 62: 3776-3782
• 10 Shoop-Worrall SJW, Kearsley-Fleet L, Thomson W. et al How common is remission in juvenile idiopathic arthritis: A systematic review. Semin Arthritis Rheum 2017; 47 (03) 331-337
• 11 Cellucci T, Guzman J, Petty RE. et al Management of Juvenile Idiopathic Arthritis 2015: a position statement from the pediatric Committee of the Canadian Rheumatology Association. J Rheumatol 2016; 43 (10) 1773-1776
• 12 Wallace CA, Giannini EH, Spalding SJ. et al Trial of Early Agressive Therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012; 64 (06) 2012-2021
• 13 Wallace CA, Ringold S, Bohnsack J. et al Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. J Rheumatol 2014; 41 (12) 2459-2465
• 14 Hissink Muller PCE, Brinkman DMC, Schonenberg D. et al A comparison of three treatment stratgies in recent onset non-systemic juvenile idiopathic arthritis: initial 3-months results of the best for kids-study. Pediatric Rheumatology 2017; 15: 11
• 15 Wallace CA, Ruperto N, Giannini E. et al Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31 (11) 2290-2294
• 16 Singh-Grewal D, Wright V, Bar-Or O. et al Pilot study of fitness training and exercise testing in polyarticular childhood arthritis. Arthritis Rheum 2006; 55: 364-372
• 17 Lelieveld OT, Armbrust W, van Leeuwen MA. et al Physical Activity in Adolescents With Juvenile Idiopathic Arthritis. Arthritis Rheum 2008; 59 (10) 1379-1384
• 18 Erhart M, Weimann A, Bullinger M. et al Psychische Komorbidität bei chronisch somatischen Erkrankungen im Kindes- und Jugendalter. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 2011; 54 (01) 66-74
• 19 Foster HE, Minden K, Clemente D. et al EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. Ann Rheum Dis 2017; 76 (04) 639-646
• 20 Guzman J, Oen K, Tucker LG. et al The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 2015; 74 (10) 1854-1860
• 21 Glerup M, Herlin T, Twilt M. Clinical Outcome and Long-term Remission in JIA. Curr Rheumatol Rep 2017; 19 (12) 75
• 22 Giancane G, Muratore V, Marzetti V. et al Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. Arthritis Res Ther 2019; 21 (01) 168
• 23 Minden K, Horneff G, Niewerth M. et al Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young Adulthood. Arthritis Care Res (Hoboken) 2019; 71 (04) 471-481
• 24 Ringold S, Weiss PF, Colbert RA. et al Childhood arthritis and rheumatology research alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2014; 66 (07) 1063-1072
• 25 Hinze CH, Holzinger D, Lainka E. et al Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J 2018; 16: 7
• 26 Horneff G, Klein A, Ganser G. et al Protocols on classification, monitoring and therapy in children’s rheumatology (PRO-KIND). Results of the working group polyarticular juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2017; 15: 78
• 27 Oommen PT, Niehues T. Sind die Leitlinien das non plus ultra? Anwendung von Leitlinien bei der JIA im klinischen Alltag. Akt Rheumatol 2015; 40: 280-283